Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful diligently but unsuccessfully to create an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last few shares of mine. My first CytoDyn post, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set out what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire employment interview which I came away with an inadequate opinion of the company.

Irony of irony, the bad opinion of mine of the business enterprise has grown steadily, although the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this technology as well as connected intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) plus the very first brand new drug application endorsement ($5 million), as well as royalty payments of five % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it has this single therapy in addition to a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an energetic business with diverse interests albeit focused on leronlimab, several disease sorts, multiple delivering presentations in addition to multiple publications.

Could it all be smoke and mirrors? That’s a question I have been asking myself from the very beginning of my interest in this company. Judging with the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a classic battleground, or even some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *